BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Knight Reports Third Quarter 2017 Results

  As at September 30, 2017, Knight had over $760,000 in cash, cash equivalents and marketable securities and 142,772,805 common shares outstanding.

  November 9, 2017

   · 

  18 min read
• 

  Business

  Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure

  Ionis earns $5 million license fee from Dynacure.

  November 9, 2017

   · 

  5 min read
• Business

  Impax Reports Third Quarter 2017 Results

  Total revenues in the third quarter 2017 were $206.4 million, a decrease of 9.4%, compared to $227.9 million in the prior year period as a decrease in sales of generic products was partially offset by an increase in sales of specialty products.

  November 9, 2017

   · 

  72 min read
• Business

  ReadCoor Collaborates With The Joint Pathology Center

  ReadCoor, a company reinventing omics and pathology with its panomic spatial sequencing platform, today announced a collaboration with The Joint Pathology Center (JPC), the premier pathology reference center for the United States government.

  November 9, 2017

   · 

  2 min read
• Business

  ArQule Reports Third Quarter 2017 Financial Results

  For the quarter ended September 30, 2017, the Company reported a net loss of $6,666,000 or $0.09 per share, compared with a net loss of $5,817,000 or $0.08 per share, for the third quarter of 2016.

  November 9, 2017

   · 

  12 min read
• Oragenics Announces Closing of $3.3 Million Preferred Stock Private Placement and $3.4 Million Debt Conversion into Equity

  Oragenics today announced that it has completed a private placement of $3.3 million of Non-Voting Series B Convertible Preferred Stock with four existing shareholders who are accredited investors including an entity affiliated with a director of the Company. Concurrently with the Preferred Stock Financing

  November 9, 2017

   · 

  8 min read
• Business

  Charles River Laboratories Announces Third-Quarter 2017 Results From Continuing Operations

  Revenue from continuing operations was $464.2 million, an increase of 9.0% from $425.7 million in the third quarter of 2016.

  November 9, 2017

   · 

  27 min read
• Business

  Nephros Reports Third Quarter 2017 Financial Results

  Total net revenues for the three months ended September 30, 2017 were approximately $916,000, compared to approximately $475,000 for the three months ended September 30, 2016.

  November 9, 2017

   · 

  12 min read
• Tetra Bio-Pharma Concludes Its First Sale of Rx Princeps Inhalation Device

  Tetra has received its first sales order from Sante Cannabis.

  November 9, 2017

   · 

  5 min read
• Biotech Bay

  Nanomix Announces Equity Financing and Collaboration With Hong Kong-Beijing Based World Technology East and RedPharm Biotechnology Companies

  The deal will focus on human health and veterinary diagnostic applications of nanomix technology and products.

  November 9, 2017

   · 

  3 min read